SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* Advanced RNA Technologies, LLC (Last) (First) (Middle) 1 KENDALL SQUARE BUILDING 200 SUITE 2203 (Street) CAMBRIDGE MA 02139 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol RXi Pharmaceuticals Corp [ RXII ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 02/05/2013
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.0001 par value	02/05/2013		J(1)		10,000	D	$0.076	41,249,266	D
Common Stock, $0.0001 par value	02/06/2013		J(1)		20,000	D	$0.086	41,229,266	D
Common Stock, $0.0001 par value	02/11/2013		J(1)		40,000	D	$0.115	41,189,266	D
Common Stock, $0.0001 par value	02/11/2013		J(1)		20,000	D	$0.095	41,169,266	D
Common Stock, $0.0001 par value	02/11/2013		J(1)		20,000	D	$0.091	41,149,266	D
Common Stock, $0.0001 par value	02/14/2013		J(1)		30,000	D	$0.116	41,119,266	D
Common Stock, $0.0001 par value	02/15/2013		J(1)		40,000	D	$0.136	41,079,266	D
Common Stock, $0.0001 par value	02/19/2013		J(1)		49,000	D	$0.19	41,030,266	D
Common Stock, $0.0001 par value	02/19/2013		J(1)		1,000	D	$0.192	41,029,266	D
Common Stock, $0.0001 par value	02/22/2013		J(1)		40,000	D	$0.16	40,989,266	D
Common Stock, $0.0001 par value	02/25/2013		J(1)		92,000	D	$0.18	40,897,266	D
Common Stock, $0.0001 par value	02/25/2013		J(1)		8,000	D	$0.182	40,889,266	D
Common Stock, $0.0001 par value	02/26/2013		J(1)		4,000	D	$0.175	40,885,266	D
Common Stock, $0.0001 par value	02/27/2013		J(1)		29,888	D	$0.16	40,855,378	D
Common Stock, $0.0001 par value	02/28/2013		J(1)		200	D	$0.16	40,855,178	D
Common Stock, $0.0001	03/01/2013		J(1)		20,000	D	$0.15	40,835,178	D
Common Stock, $0.0001	03/04/2013		J(1)		50,000	D	$0.145	40,785,178	D
Common Stock, $0.0001 par value	03/05/2013		J(1)		30,000	D	$0.145	40,755,178	D
Common Stock, $0.0001 par value	03/06/2013		J(1)		36,570	D	$0.149	40,718,608	D
Common Stock, $0.0001 par value	03/07/2013		J(1)		50,000	D	$0.195	40,668,608	D
Common Stock, $0.0001 par value	03/08/2013		J(1)		50,000	D	$0.194	40,618,608	D
Common Stock, $0.0001 par value	03/11/2013		J(1)		100,000	D	$0.233	40,518,608	D
Common Stock, $0.0001 par value	03/11/2013		J(1)		100,000	D	$0.24	40,418,608	D
Common Stock, $0.0001 par value	03/11/2013		J(1)		100,000	D	$0.221	40,318,608	D
Common Stock, $0.0001 par value	03/11/2013		J(1)		100,000	D	$0.273	40,218,608	D
Common Stock, $0.0001 par value	03/12/2013		J(1)		100,000	D	$0.272	40,118,608	D
Common Stock, $0.0001 par value	03/14/2013		J(1)		7,500	D	$0.334	40,111,108	D
Common Stock, $0.0001 par value	03/14/2013		J(1)		126,843	D	$0.331	39,984,265	D
Common Stock, $0.0001 par value	03/15/2013		J(1)		100,000	D	$0.325	39,884,265	D
Common Stock, $0.0001 par value	03/18/2013		J(1)		52,900	D	$0.348	39,831,365	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sales of non-derivative securities sold in the manner required under Rule 144 for Affiliates of of the Issuer.

	Alexey Wolfson, Manager	04/11/2013
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.